Welcome to our blog

In January 2026, the FDA approved a medication that many patients have been eagerly anticipating: oral Wegovy . This is the first pill form of a GLP-1 medication officially approved for chronic weight management. Previously, Wegovy (semaglutide) was available only as a once-weekly injection. While an oral version of semaglutide (Rybelsus) existed for diabetes, there had never been an FDA-approved pill specifically for weight loss. This approval marks a significant advancement

The last two weeks have brought historic changes for people seeking GLP-1 weight-loss medications like Wegovy and Zepbound. Between the November 6 White House agreement with drug-makers and the latest announcement from Novo Nordisk on November 17 to reduce the cash price of Wegovy, Americans are now seeing meaningful improvements in access and affordability. As a board-certified obesity medicine physician, I’m breaking down what these updates mean — especially for patients

If you're currently using compounded semaglutide or tirzepatide as part of your medical weight loss journey, you've likely seen news about changes from the FDA . You may be wondering how these changes affect your treatment. Here’s what’s happening, how it might impact you, and what your next steps could be. 📣 FDA Removes Semaglutide & Tirzepatide from the Shortage List As of early April 2024 , the FDA has officially removed semaglutide (Wegovy) and tirzepatide (Zepbound)

As a primary care physician specializing in obesity medicine, I hear this phrase often from patients: “I just can’t stop thinking about food.”  It’s a sentiment many can relate to, but not everyone understands what it means to experience “food noise” on a constant basis. For some, this internal dialogue about eating—what to eat, when to eat, how much to eat—can feel overwhelming, distracting, and exhausting. In the context of obesity and weight management, this mental chatter

Not all compounded weight loss medications are created equally. Here’s why you should be cautious:

Welcome to the final installment of our blog series on obesity and medical weight management. In this post, we will discuss strategies to mitigate metabolic adaptation we just learned about in part IV and strategies to get the metabolic dance back on beat and restore the balance between all the hunger and appetite hormones and signals. Remember that when we are exposed to increased stress, disrupted sleep, irregular eating habits, and decreased caloric intake, our neurohormo

But you didn't think you could outsmart your body that easily did you? There's another concept to learn: Metabolic adaptation

In part II of this blog series, we explored the harmonious dance of ghrelin, leptin, and insulin in managing your energy, hunger, and weight. In part III, let's discuss what happens when this intricate choreography between ghrelin, leptin, insulin, and incretins encounters an imbalance and how it can sway the balance of weight management. The Metabolic Dance: When there's harmony In our previous discussions, we explored how ghrelin signals hunger, while leptin triggers the se

For part II of this blog series, we are going to look closer at the intricate world of your body's metabolic dance. Imagine this dance as a well-choreographed performance where hormones like ghrelin, leptin, insulin, and incretins, along with the brain, lead the way. There is a delicate balance that keeps this dance in perfect harmony. Before starting, understand that at its core, hunger is a primal survival mechanism deeply ingrained in the evolutionary history of our specie

According to the Centers for Disease Control and Prevention , obesity affects over 40 percent of U.S. adults and increases the risks for heart disease, cancer, diabetes, stroke and musculoskeletal problems. In 2013, the American Medical Association officially labeled obesity as a disease and there has been an increasing number of physicians devoting all or a portion of their practice to obesity care. Just this past year, I became certified by the American Board of Obesity